Patients treated with Ditropan XL experienced between 15 to 18 fewer urge incontinence episodes per week. In clinical trials, Ditropan XL was demonstrated to be well-tolerated by patients. The incidence of dry mouth was dose-related. In all controlled trials, seven percent of patients treated with Ditropan XL discontinued because of adverse events. At present, overactive bladder is widely underdiagnosed and undertreated.
Overactive bladder can have a profound impact on patients and disrupt daily routines and activities.
Some patients may become socially isolated or even housebound because they fear the embarrassment of having urinary accidents in public. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.